Please assess the completion status of the following clinical trial:

Trial Title: A Study of Tocilizumab Added to DMARDs in Patients With Moderate to Severe Rheumatoid Arthritis and an Inadequate Response to DMARDs.

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* adult patients, \>/= 18 years of age~* moderate to severe active rheumatoid arthritis of \>/=6 months duration~* inadequate clinical response to current non-biologic DMARDs~* current DMARDs must be at stable dose for 8 weeks prior to study entry~* oral corticosteroids (\</=10mg/day prednisone or equivalent) and NSAIDs must be at stable dose for \>/=4 weeks prior to screening~Exclusion Criteria:~* rheumatic autoimmune disease other than RA~* history of or current inflammatory joint disease other than RA~* previous treatment with any biologic DMARD~* functional class IV as defined by the ACR classification~* intra-articular or parenteral corticosteroids within 6 weeks prior to screening

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).